MedDataX Logo

Neuromuscular Electrical Stimulation (NMES) and Muscle Protein Accretion (ES-PRO)

NCT ID: NCT01615276

Last Updated: 2013-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-10-31

Study Completion Date

2013-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the present study, the effect of a bolus of intrinsically labeled milk directly after one-legged NMES will be studied.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Neuromuscular Electrical Stimulation Ageing Protein ingestion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Protein ingestion

Protein ingestion directly after the contralateral leg received NMES

Group Type PLACEBO_COMPARATOR

No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES

Intervention Type DEVICE

No neuromuscular electrical stimulation (NMES) will be applied in the control leg

Protein ingestion after NMES

Ingestion of intrinsically labeled protein, directly after one hour of Neuromuscular electrical stimulation (NMES)

Group Type EXPERIMENTAL

Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)

Intervention Type DEVICE

One our of one-legged neuromuscular electrical stimulation (NMES)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)

One our of one-legged neuromuscular electrical stimulation (NMES)

Intervention Type DEVICE

No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES

No neuromuscular electrical stimulation (NMES) will be applied in the control leg

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male
* Age 65 - 85 years
* 18.5 \< BMI \< 30 kg∙m2

Exclusion Criteria

* Type II diabetes
* All co morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthrosis, arthritis, spasticity/rigidity, all neurological disorders, paralysis, hip/knee surgery).
* Use of anticoagulants, blood diseases, allergy for lidocaine
* Use of NSAIDs and acetylsalicylic acid
* Patients suffering from PKU (Phenylketonuria)
* Presence of implantable cardioverter defibrillator and/or pacemaker
* Performed regular resistance type exercise in the past 6 months
Minimum Eligible Age

65 Years

Maximum Eligible Age

85 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Maastricht University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Luc JC van Loon, PhD

Role: PRINCIPAL_INVESTIGATOR

Maastricht UMC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Maastricht University Medical Centre

Maastricht, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Gorissen SHM, Trommelen J, Kouw IWK, Holwerda AM, Pennings B, Groen BBL, Wall BT, Churchward-Venne TA, Horstman AMH, Koopman R, Burd NA, Fuchs CJ, Dirks ML, Res PT, Senden JMG, Steijns JMJM, de Groot LCPGM, Verdijk LB, van Loon LJC. Protein Type, Protein Dose, and Age Modulate Dietary Protein Digestion and Phenylalanine Absorption Kinetics and Plasma Phenylalanine Availability in Humans. J Nutr. 2020 Aug 1;150(8):2041-2050. doi: 10.1093/jn/nxaa024.

Reference Type DERIVED
PMID: 32069356 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MEC 12-3-020

Identifier Type: -

Identifier Source: org_study_id